Huge congratulations to the Cambridge Crystallographic Data Centre (CCDC), the University of Leeds, Tianjin University, and AbbVie Inc. who recently won an Outstanding Manuscript Award from the American Association of Pharmaceutical Scientists (AAPS) for a published research paper in the scientific journal Pharmaceutical Research investigating AIDS drug Ritonavir – ‘Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.’
Dr Jürgen Harter, CEO of CCDC said “This…
Domainex share their latest updates in recent newsletter including:
Receiving a King's Award for Enterprise
Expansion plans in UK and US
The launch of new Cryo-EM and Flow Cytometry services
Latest recruits
Read the full newsletter
Our August eNews is here: 'Embracing Change and Unlocking Opportunities in the Evolving Life Science Industry' ✅ This month's overview from Tony Jones, CEO, One Nucleus✅ Be at Your Best with One Nucleus Events✅ ON Helix 2023 - When do Good Neighbours become Good Business Partners?✅ One Nucleus wins Gold Award for Green Impact✅ The Evolving Role of Online Innovation Workshops via One Nucleus Read it here: https://bit.ly/3KMjntR
OMass Therapeutics Expands Leadership Team with Two New Appointments
Appointment of two senior executives in newly created roles
Peter Phillips M.D., Ph.D. joins as Senior Vice President of Clinical Development and Julia Sampson Ph.D. joins as Vice President of Non-clinical Development
Oxford, United Kingdom – 02 August 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the expansion of its leadership team with the appointment of two senior executives in newly…
Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.
The transaction creates a significant competitive advantage for Sygnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market. Together,…
Check out a round up of news, updates and highlights from ValiRx this month, including their attendance at ON Helix 2023: ValiRx News Roundup - August 2023
"ValiRx and Inaphaea teams attend On Helix
On 6 July, ValiRx CEO Dr Suzy Dilly, Corporate Development Manager Mark Treharne, and Inaphaea's Head of Strategic Development, Dr Andrew Carnegie attended On Helix in Cambridge.
The conference, which has become a staple in the life sciences events calendar, addresses the key trends in bio innovation, from developments in life science and technology research to their…
Metrion is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme
New service with GLP certification further strengthens Metrion’s support for small molecule therapeutics development
Cambridge, UK, 01 August 2023: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has received notification from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) that the Company is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme,…
AMSBIO announce a new range of pre-made Nano-Lantern lentivirus products that utilize a proprietary lentiviral vector system to enable highly sensitive and precise in vivo luminescence imaging.
This cutting-edge Nano-Lantern lentivirus technology, which consists of an enhanced Renilla-Luciferase connected to an Orange Fluorescent protein (OFP), represents a significant improvement over previous methods and is poised to revolutionize many in vivo imaging applications.
Fluorescent markers and bioluminescence are widely used techniques for in vivo imaging in living cells. While…
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
The virtual patient will be created in the laboratory, by taking samples of a patient’s own tumour cells and immune system, and will then be presented with a range of new immunotherapies developed by the…
Alexion, AstraZeneca’s rare disease subsidiary, is acquiring a portfolio of preclinical gene therapy programs from Pfizer. The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on AstraZeneca’s capabilities in genomic medicine.
Under the agreement, Alexion will purchase and license the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total of up to $1 billion, plus tiered royalties on sales. Alexion plans to close the transaction in Q3 2023.
Marc Dunoyer, CEO, Alexion, AstraZeneca Rare Disease, said, “Today’s…